CTNI-04. ACTIVITY OF LAROTRECTINIB IN TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) METASTASES

BACKGROUND: NTRK gene fusions occur in a range of tumor types, including those with CNS metastases. Larotrectinib, a highly selective FDA- and EMA- approved TRK inhibitor, demonstrated an objective response rate (ORR) of 79% across various cancers (Hong et al. Lancet Oncol. 2020). We report data on...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Patel, Jyoti D, Farago, Anna F, Hong, David S, Lassen, Ulrik N, Leyvraz, Serge, Park, Keunchil, Sohal, Davendra P S, Solomon, Benjamin, Reeves, John A, Dima, Laura, Brega, Nicoletta, Drilon, Alexander
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
Clinical Trials: Non-Immunologic
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650347/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.171
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky